Can Lipid-Lowering Drugs Reduce the Risk of Cholelithiasis? A Mendelian Randomization Study
Hao Dong,Rong Chen,Fang Xu,Fang Cheng
DOI: https://doi.org/10.2147/clep.s439642
2024-02-22
Clinical Epidemiology
Abstract:Hao Dong, 1, &ast Rong Chen, 2, &ast Fang Xu, 3, &ast Fang Cheng 4 1 Department of Gastroenterology and Hepatology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, People's Republic of China; 2 Department of Rehabilitation Medicine, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, People's Republic of China; 3 Clinical Medical Laboratory Center, Taizhou People's Hospital, Taizhou, Jiangsu, 225300, People's Republic of China; 4 Department of Gastroenterology, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fang Cheng, Department of Gastroenterology, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, No. 1 Yintan Road, Dongxihu District, Wuhan, 430023, Hubei Province, People's Republic of China, Email Background and Aims: Cholelithiasis etiology intricately involves lipid metabolism. We sought to investigate the plausible causal link between genetically proxied lipid-lowering medications—specifically HMGCR inhibitors, PCSK9 inhibitors, and NPC1L1 inhibitors—and cholelithiasis risk. Methods: Our study utilized two genetic instruments for exposure to lipid-lowering drugs. These instruments encompassed genetic variants linked to low-density lipoprotein (LDL) cholesterol within or in proximity to drug target genes, along with loci governing gene expression traits of these targets. Effect estimates were derived through Inverse-variance-weighted MR (IVW-MR) and summary-data-based MR (SMR) methods. Results: Higher HMGCR-mediated LDL cholesterol levels (IVW-MR, OR = 2.15, 95% CI = 1.58– 2.94; P = 0.000) and increased HMGCR expression (SMR, OR = 1.19, 95% CI = 1.04– 1.37; P = 0.014) are linked to elevated cholelithiasis risk, suggesting potential benefits of HMGCR inhibition. In contrast, higher PCSK9-mediated LDL cholesterol levels (IVW-MR, OR = 0.72, 95% CI = 0.56– 0.94; P = 0.015) and increased PCSK9 expression (SMR, OR = 0.90, 95% CI = 0.82– 0.99; P = 0.035) both correlate with lower cholelithiasis risk, indicating that PCSK9 inhibition may elevate this risk. Nevertheless, no substantial link emerged between NPC1L1-mediated LDL cholesterol or NPC1L1 expression and cholelithiasis in both IVW-MR and SMR analyses. Conclusion: This MR investigation affirms the causal link between the utilization of HMGCR inhibitors and a diminished risk of cholelithiasis. Additionally, it indicates a causal link between PCSK9 inhibitors use and increased cholelithiasis risk. However, no significant correlation was found between NPC1L1 inhibitors use and cholelithiasis risk. Keywords: cholelithiasis, lipid-lowering drugs, Mendelian randomization analysis, HMGCR inhibitors, PCSK9 inhibitors, NPC1L1 inhibitors Cholelithiasis represents a significant global public health concern, affecting an estimated 10–20% of adults worldwide. 1,2 Over 20% of individuals with cholelithiasis encounter symptoms or complications, including potential life-threatening conditions like gallstone-related pancreatitis, acute cholecystitis, and acute cholangitis. 1 These stones can be categorized into two main types based on composition: pigment stones and cholesterol stones. 3 In Western nations, approximately 80% to 90% of gallstones extracted through surgery consist of cholesterol stones. 4 The formation of cholesterol stones is often linked to cholesterol supersaturation in the bile. 4 Previous research has explored the relationship between plasma cholesterol levels and gallstones, yielding varying results. Some studies suggest a positive correlation, 5–7 while others propose a negative correlation, 8,9 and there are studies indicating no significant correlation. 10 Lipid-lowering medications, including 3-hydroxy-3-methylglutaryl–CoA reductase (HMGCR) inhibitors commonly referred to as statins, Niemann-PickC1–like1 (NPC1L1) inhibitors such as ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors like alirocumab, are crucial for primary and secondary prevention of cardiovascular diseases and are widely used worldwide. 11–13 These medications not only lower serum low-density lipoprotein cholesterol concentrations but also affect cholesterol metabolism in the liver and/or its secretion into the bile. 11–14 In a recent Mendelian randomization (MR) study, a link emerged between reduced serum total cholesterol levels and heighten -Abstract Truncated-
public, environmental & occupational health